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ABSTRACT
Background
Systematic reviews (SRs) have become increasingly popular to a wide range of stakeholders.
We set out to capture a representative cross-sectional sample of published SRs and examine
them in terms of a broad range of epidemiological, descriptive, and reporting characteristics,
including emerging aspects not previously examined.
Methods and Findings
We searched Medline for SRs indexed during November 2004 and written in English.
Citations were screened and those meeting our inclusion criteria were retained. Data were
collected using a 51-item data collection form designed to assess the epidemiological and
reporting details and the bias-related aspects of the reviews. The data were analyzed
descriptively. In total 300 SRs were identified, suggesting a current annual publication rate of
about 2,500, involving more than 33,700 separate studies including one-third of a million
participants. The majority (272 [90.7%]) of SRs were reported in specialty journals. Most reviews
(213 [71.0%]) were categorized as therapeutic, and included a median of 16 studies involving
1,112 participants. Funding sources were not reported in more than one-third (122 [40.7%]) of
the reviews. Reviews typically searched a median of three electronic databases and two other
sources, although only about two-thirds (208 [69.3%]) of them reported the years searched.
Most (197/295 [66.8%]) reviews reported information about quality assessment, while few (68/
294 [23.1%]) reported assessing for publication bias. A little over half (161/300 [53.7%]) of the
SRs reported combining their results statistically, of which most (147/161 [91.3%]) assessed for
consistency across studies. Few (53 [17.7%]) SRs reported being updates of previously
completed reviews. No review had a registration number. Only half (150 [50.0%]) of the reviews
used the term ‘‘systematic review’’ or ‘‘meta-analysis’’ in the title or abstract. There were large
differences between Cochrane reviews and non-Cochrane reviews in the quality of reporting
several characteristics.
Conclusions
SRs are now produced in large numbers, and our data suggest that the quality of their
reporting is inconsistent. This situation might be improved if more widely agreed upon
evidence-based reporting guidelines were endorsed and adhered to by authors and journals.
These results substantiate the view that readers should not accept SRs uncritically.
The Editors’ Summary of this article follows the references.
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PLoS MEDICINEIntroduction
Systematic reviews (SRs) have become increasingly popular
in medicine. Clinicians read them as an efﬁcient way of
keeping up-to-date with their content area. Clinical practice
guideline developers use them as a starting point for
guideline development. Granting agencies require them as
an evidence base for the need to conduct new research [1],
and healthcare journals are moving in the same direction [2].
These different stakeholders should be encouraged to use
SRs, particularly if they are of high quality and have taken
steps to minimize bias.
The principal opportunity to estimate how a SR was
designed and conducted is by examining its report. In one of
the ﬁrst evaluations of SRs, in 1987 Sacks and colleagues
examined 83 SRs regarding their adequacy of reporting, using
23 characteristics covering six domains [3]. The authors noted
that reporting was generally poor, with between 1 and 14
characteristics adequately reported (mean ¼ 7.7; standard
deviation ¼ 2.7). For example, only six (7%) of the 83 reports
mentioned use of a protocol to conduct the SR. A 1999
update [4] of a 1987 publication [5] found little improvement
in the quality of reporting of SRs over time. Others have
recently reported similar results, namely, that the quality of
reporting of SRs is less than optimal [6,7].
Some possible limitations of these evaluations are that they
did not set out to examine epidemiological aspects of SR
reports, such as their publication prevalence and different
types of SRs being published, nor did they examine a
representative sample of published SRs. Typically the focus
of such examinations is in speciﬁc health care areas [8–11] or
type of SR [12,13]. Also, some of these evaluations are
relatively old and thus could not address new and emerging
issues relevant for SRs, such as the frequency with which they
are updated. Our sampling strategy allowed us to compre-
hensively examine recent SRs across all application areas.
We set out to capture a cross-sectional sample of all
recently published SRs and examine them in terms of a broad
range of epidemiological and reporting characteristics,
including emerging issues not previously examined.
Methods
Definition
There is no standard deﬁnition of an SR. We counted a
report as an SR if the authors’ stated objective was to
summarize evidence from multiple studies and the article
described explicit methods, regardless of the details provided.
Search
We believed that one month’s publications would provide a
few hundred eligible studies that would be enough to give a
reliable summary of the literature. The Cochrane library is
reissued quarterly. November 2004 was selected as it was the
most recent month including new Cochrane reviews.
MEDLINE was searched to identify potential systematic
reviews entered into Medline in November 2004. We used
Montori’s balanced ﬁve-term search strategy (speciﬁcity .
sensitivity [14]), and supplemented it with his balanced three-
term strategy (sensitivity . speciﬁcity), modiﬁed slightly:
Ovid MEDLINE 1966 to Feb Week 1 2005 (searched Feb 18
2004), (1) 200411$.ed; (2) limit 1 to English (3) 2 and (cochrane
database of systematic reviews.jn. or search.tw. or meta-
analysis.pt. or medline.tw. or systematic review.tw. or ((meta-
analysis.mp,pt. or review.pt. or search$.tw.) and methods.ab.))
In the case of the three-term strategy we required that the
string ‘‘methods’’ appear in the abstract. We further limited
the search to SRs reported in English due to the additional
resources required to translate SRs published in other
languages. The search results were uploaded into an
Internet-based management program (Systematic Review
System).
Screening
Two members of the research team independently
screened the citations (title and abstract). One reviewer
subsequently screened the full text articles of citations
meeting our deﬁnition and those in which eligibility
remained unclear. A second reviewer independently screened
a 10% random sample. When it was clear that the intent of
the authors was a literature review (e.g., authors identiﬁed the
review as a brief overview with no speciﬁc review question), as
opposed to an SR, articles were excluded. All other articles
were included.
Data Collection and Analysis
Data collection was completed using a form that included
51 questions. Here we summarize a subset focusing on
epidemiological and descriptive characteristics, including
those with a potential for bias (Tables 1 and 2). We classiﬁed
the Cochrane Database of Systematic Reviews, where Co-
chrane reviews are published, as a specialty journal. Reviews
were classiﬁed according to their focus: therapeutic (e.g.,
treatment or prevention), diagnostic/prognostic (e.g., clinical
prediction rules), epidemiology (e.g., incidence, prevalence),
or other (e.g., education).
Two reviewers independently pilot-tested the form on a
separate set of ﬁve articles. Each article was screened
independently by one of three team members with a 5%
sample screened in duplicate by two reviewers. Any un-
certainties were discussed among the data extractors, and
conﬂicts were resolved by coming to consensus.
All data analyses were performed using SPSS (version 13;
http://www.spss.com). The analysis was descriptive. Data are
summarized as frequency or median and interquartile range
(IQR). We completed the one a priori subgroup analysis
comparing Cochrane reviews to non-Cochrane reviews in
terms of their reporting characteristics with a potential for
bias.
Results
Search
Our search identiﬁed 1,046 records (Figure 1). Initial
screening excluded 291 records, including two duplicates.
The remaining 758 full-text articles were retrieved for
additional scrutiny, of which 458 proved ineligible. Agree-
ment was excellent between reviewers across the screening
phases (kappa ¼ 0.86). The majority of articles (78.2%) were
excluded because they did not report any methods explicitly.
We thus included 300 eligible reports for full data extraction.
Prevalence of Publishing SRs
We identiﬁed 300 SRs that were indexed in Medline in
November 2004. Cochrane reviews contributed nearly half of
these reviews (125 [41.7%]). Given that Cochrane reviews are
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Characteristics of Systematic Reviewspublished and indexed quarterly, this corresponds to an
estimated annual frequency of approximately 2,500 publica-
tions, of which about 20% are Cochrane reviews. Although
the SRs were all indexed in November 2004 they had been
published between 1999 and 2004 (2004 ¼ 96%). One review
was published in the Cochrane Library and a paper-based
journal; both are included here.
Using our deﬁnition of an SR we had difﬁculty in deciding
on whether 30 (10%) of the included reviews were actually
systematic. We completed a post-hoc sensitivity analysis with
and without these 30 reviews. The results did not change in a
meaningful way. As such all of the analyses presented here
include all 300 SRs.
Overall Epidemiology Characteristics
The 300 reviews were published in 132 journals, with most
journals publishing only one SR indexed during the month
although three journals each published four or more SRs
(Table 1). Most reviews were published in journals with
impact factors of ﬁve or less, although four SRs were
published in journals with a high impact factor (.15). Nearly
half of the SRs (135 [45%]), including all of the Cochrane SRs,
did not have an impact factor. The reviews included a median
of four authors although 24 (8%) of the reviews were single
authored (Tables 1 and 2). One-quarter (76 [25.3%]) of the
corresponding authors were from the United Kingdom with
four countries (UK, US, Australia, and Canada) accounting
for two-thirds of the SRs published during the month (Table
1). The majority of the reviews (213/300 [77%]) were classiﬁed
as therapeutic—of which slightly more than half (125/213
[59%]) were Cochrane reviews—38/300 (13%) as epidemiol-
ogy reviews, and 23/300 (8%) as diagnostic/prognostic reviews.
Forty-six (15%) of the 300 reports were categorized as other,
such as assessing the quality of immunosuppression trials in
kidney transplantation [15].
Nearly half (142 [47.3%]) of the reviews reported examin-
ing the health effects of pharmacological interventions with
the only a small percentage (24 [8.0%]) of reviews reported
examining complementary and alternative medicine. The
most common review classiﬁcation (International Classiﬁca-
tion of Diseases 10 [ICD-10]) was mental and behavioural
disorders (40 [13.3%]).
Descriptive Characteristics
Almost all of the SRs (272 [90.7%]) were published in
specialty journals (Table 2). Few reviews (53 [17.7%]) reported
being updates of previously completed reviews, although, of
the therapeutic reviews, more than one-third of the Cochrane
ones were updates (47/125 [37.6%]); almost no non-Cochrane
reviewswerereportedasupdates(2[2.3%]).TheSRsincludeda
medianof16studiesinvolving1,112participants,althoughthis
number varied considerably by review category. Therapeutic
reviews were the smallest and, of these, Cochrane reviews
includedfewerstudies(median¼8)andparticipants(median¼
769) compared to non-Cochrane reviews (median number of
studies ¼ 23; median number of participants ¼ 1,137). Those
reviews with a diagnostic/prognostic focus were the largest by
far (Table 2). One hundred sixty-one reviews (53.7%) reported
combiningtheresultsoftheirincludedstudiesstatistically(i.e.,
meta-analytical synthesis). Most reviews (166/227 [73.1%])
reported on some aspect of harms. However, few reviews (61/
254 [24%]) considered economic issues in their report.
Reporting Characteristics Related to Potential for Bias
Half (150 [50%]) of the review reports used the term
‘‘systematic review’’ or ‘‘meta-analysis’’ in the title or abstract
with little variation across review category. However, of the
therapeutic reviews, Cochrane reviews were less likely to use
‘‘systematic review’’ and/or ‘‘meta-analysis’’ in the title or
abstract (49 [39.2%]) compared to non-Cochrane reviews (60
[68.2]%). Although close to half (139 [46.3%]) of the reviews
reported working from a protocol, therapeutic reviews were
more likely to report using a protocol than were other types
Table 1. Epidemiology of Systematic Reviews
Category Characteristic Number (%),
of n ¼ 300
Total number of
journals
132
Number of
journals publishing
One review 102 (77.3)
Two reviews 21 (15.9)
Three reviews 6 (4.5)
Four reviews or more 3 (2.3)
Journal impact
factor by review
0.0–5.0 106 (35.3)
5.1–10.0 19 (6.3)
10.1–15.0 1 (0.3)
.15 4 (1.3)
Not found 35 (11.7)
N/A 135 (45.0)
Year of publication 2004 288 (96.0)
2003 6 (2.0)
2002 1 (0.3)
2001 3 (1.0)
2000 1 (0.3)
1999 1 (0.3)
Number of authors 1 24 (8.0)
2–3 125 (41.7)
4–6 128 (42.7)
 7 23 (7.7)
Country of
corresponding author
UK 76 (25.3)
US 68 (22.7)
Australia 31 (10.3)
Canada 28 (9.3)
The Netherlands 17 (5.7)
Germany 10 (3.3)
New Zealand 10 (3.3)
Other (,10 reviews/country,
30 countries)
60 (20.0)
Focus of review
a Therapeutic
b 213 (71.0)
Diagnosis/Prognosis 23 (7.7)
Epidemiology 38 (12.7)
Other (e.g., education, review
of quality of RCTs)
46 (15.3)
Common ICD-10 Mental and behavioural disorders 40 (13.3)
Diseases of the circulatory system 33 (11.0)
Malignant neoplasms 22 (7.3)
Infections and parasitic diseases 20 (6.7)
Diseases of the digestive system 20 (6.7)
Pregnancy, childbirth, and the
puerperium
21 (7.0)
aDoesnotequal100%,assomereviewscomparedinterventionsinmorethanonecategory.
bTherapeutic refers to reports in which review focus was treatment or prevention.
N/A, not applicable.
doi:10.1371/journal.pmed.0040078.t001
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Characteristics of Systematic Reviewsof reviews (Table 3). Within the therapeutic review category
almost every Cochrane review reported a protocol (122/125
[97.6%]), but only a small minority of non-Cochrane reviews
did (10/88 [11.4%]).
The majority (211/293 [72.0%]) of reviews reported study
design eligibility criteria, although this varied across and
within review category. Of the therapeutic reviews almost all
of Cochrane ones included randomized controlled trials
Table 2. Descriptive Characteristics of Included Systematic Reviews
Category Characteristics Overall
a,
n ¼ 300
Therapeutic, n ¼ 213 Diagnosis/
Prognosis
b,
n ¼ 23
Epidemiology,
n ¼ 38
Other
n ¼ 46
Cochrane,
n ¼ 125
c
Non-Cochrane,
n ¼ 88
Journal type General, n (%) 28 (9.3) 0 (0.0) 16 (18.2) 4 (17.4) 4 (10.5) 8 (17.4)
Specialty, n (%) 272 (90.7) 125 (100.0) 72 (81.8) 19 (82.7) 34 (89.5) 39 (84.8)
Number of authors,
median (IQR)
4 (2–5) 3 (3–4) 3.5 (2.3–5) 4 (4–6) 3 (2–5) 4 (2–5)
Update of a previous
review, n (%)
53 (17.7) 47 (37.6) 2 (2.3) 0 (0.0) 2 (5.3) 5 (10.9)
Types of interventions
d Pharmacological
conventional, n (%)
142 (47.3) 84 (67.2) 47 (53.4) 3 (13.0) 7 (18.4) 13 (28.3)
Nonpharmacological
conventional, n (%)
113 (37.7) 41 (32.8) 43 (48.9) 14 (60.9) 6 (15.8) 18 (39.1)
Complementary and
alternative medicine, n (%)
24 (8.0) 11 (8.8) 11 (12.5) 0 (0.0) 1 (2.6) 1 (2.2)
No intervention, n (%) 42 (14.0) 0 (0.0) 3 (3.4) 6 (26.1) 24 (63.2) 12 (26.1)
Number of included studies n 289 125 84 20 36 42
Median (IQR) 16 (7–30) 8 (4–16) 23 (12–38) 39 (21–67) 31 (16–50) 27 (12–54)
Number of participants
in included studies
n 215 114 56 12 23 22
Median (IQR) 1,112
(322–3,750)
769
(191–2,151)
1,137
(593–4,028)
14,523
(2,555–86,792)
2,189
(1,074–19,670)
1,644
(668–34,333)
Quantitative synthesis
performed, n (%)
161 (53.7) 86 (68.8) 42 (47.7) 11 (47.8) 14 (36.8) 13 (28.3)
Harms considered
e, n (%) 166/227 (73.1) 105/122 (86.1) 44/77 (57.1) 7/13 (53.8) 4/9 (44.4) 17/22 (77.3)
Economics (i.e., costs)
considered
e, n (%)
61/254 (24.0) 38/124 (30.6) 13/83 (15.7) 7/20 (35.0) 1/12 (8.3) 10/32 (31.3)
aTotals in rows do not equal ‘‘overall’’ as some reviews had multiple foci.
bEighteen diagnostic focus, two prognosis focus, two both.
cThis total does not account for all Cochrane reviews in the sample; four Cochrane reviews were classified in ‘‘Other’’
dDoes not equal 100%, as some reviews contained data in more than one category.
eDenominator of fractions indicate the number of reports where the variable concerned was considered relevant to the review.
doi:10.1371/journal.pmed.0040078.t002
Figure 1. Flow of Citations through the Cross-Sectional Identification and Retrieval of Systematic Reviews Indexed in Medline during November 2004
doi:10.1371/journal.pmed.0040078.g001
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Characteristics of Systematic Reviews(RCTs) only (123/125 [98.4%]), whereas slightly less than half
of the non-Cochrane reviews had such restrictions (42/88
[47.7%]). Between 45% and 73% of the reviews in other
categories did not specify any study design eligibility criteria
(Table 3). About one-third of the reviews (109 [36.3%]) did
not report whether they had any publication status eligibility
criteria. Those reviews that did provide this information
tended to include both published and unpublished docu-
ments (123 [41%]). Nearly half (134 [44.7%]) of the SRs did
not report whether they had eligibility criteria based on
language of reports. Of those that did provide this informa-
tion, most (110 [36.7%]) included all languages (Table 3). Of
the therapeutic reviews, only one Cochrane review (1/125
[0.8%]) reported limiting to reports of studies written in
English, whereas about one third of non-Cochrane reviews
reported this information (27/88 [30.7%]).
Reviews reported searching a median of three electronic
databases and two other sources, although therapeutic
reviews reported searching more sources than did other
types of reviews (Table 3). For therapeutic reviews, Cochrane
SRs typically searched twice as many databases compared to
non-Cochrane SRs (median: four versus two, respectively).
Approximately two-thirds (208 [69.3%]) of the reviews
reported on the years covered for their electronic searches.
There was little consistency concerning the electronic search
information provided in SR reports. Of the therapeutic
reviews, the majority of Cochrane reviews (98/125 [78.3%])
provided a full Boolean strategy, whereas only a minority of
non-Cochrane reviews (16/88 [18.2%]) provided this informa-
tion. Search strategies were reported in 10.9%–26.3% for the
other review categories (Table 3). About half (145 [48.3%]) of
the reviews reported on whether they considered duplicates
as part of their overall approach to searching. For therapeu-
tic reviews, twice as many Cochrane SRs (86/125 [68.8%])
considered duplicates compared to non-Cochrane reviews
(30/88 [34.1%]).
Approximately half (143/280 [51.1%]) of the reviews
reported at least one primary outcome, with reviews typically
reporting a median of ﬁve outcomes, although therapeutic
reviews reported nearly double this number (median ¼ 9; see
Table 3). For therapeutic reviews, the majority of Cochrane
ones reported a primary outcome (97/125 [77.6%]), of which
only a minority (14/97 [14%]) reported a statistically
favourable result for this outcome whereas only about a
third of non-Cochrane reviews reported a primary outcome
(32/86 [37.2%]), of which half reported a statistically
favourable result (16/32 [50%]). Two-thirds of the reviews
(197/295 [66.8%]) reported information about quality assess-
ment of their studies. For therapeutic reviews, all the
Cochrane ones reported assessing the quality of included
studies whereas only half of the non-Cochrane did (43/87
[49.4%]).
Most reviews (208 [69.3%]) reported on the ﬂow of
information throughout the review process, although there
was little consistency as to how this ﬂow was reported, with
only a minority (20 [6.7%]) including the use of a QUOROM-
like ﬂow diagram (Table 3). Most reviews (250 [83.3%])
reported some information concerning the reasons for
excluding studies, although, like the ﬂow of information
through the review, there was little consistency and com-
pleteness in how exclusions were reported (Table 3). Grey
literature was reported to be included in 132 (44%) of SRs
with minimal differences across the review categories or
within the therapeutic review category (Table 3).
Of those reviews reporting a quantitative synthesis, the vast
majority (147/161 [91.3%]) reported assessing for consistency
across the studies. However, less than one-quarter of the
reviews (68/294 [23.1%]) reported assessing for publication
bias. For therapeutic reviews, about twice as many Cochrane
SRs (40/125 [32.0%]) reported assessing for publication bias
compared to non-Cochrane reviews (16/87 [18.4%]). Funding
sources were not reported in 122 (40.7%) of the reviews. A
small number of reviews (7 [2.3%]) reported being funded by
for-proﬁt sources (Table 3). Of the therapeutic reviews that
reported funding source information, nearly twice as many
were Cochrane reviews (101/125 [80.8%]) compared to non-
Cochrane reviews (44/88 [50%]). No SR in our sample
reported a registration number.
Discussion
Our study shows that SRs are now being produced in large
numbers, with about 2,500 new publications indexed annually
on Medline, of which about one-ﬁfth are Cochrane reviews.
This value is an underestimate of the total number of new
non-Cochrane SRs, as we examined only a single database and
our searching might not have identiﬁed all SRs, and we
restricted our study to English-language publications.
Our results indicate that SRs predominantly address
questions about the effectiveness of interventions, and about
half of them report combining their results statistically.
Recent SRs include more studies and participants than
previously reported [4–6], and while Cochrane reviews are
smaller than other therapeutic reviews in our sample, their
size corresponds to more recent data on Cochrane reviews
[16]. Similarly, and like randomized trials [17], SRs are
typically published in specialty journals.
There are some areas in which the quality of reporting has
improved over time, such as the use of protocols [3] and
quality assessment [18]. Similarly, very few reviews reported
being funded by commercial sources, for which such funding
has been associated with bias in the results of clinical trials
[19].
It is too early to comment on the signiﬁcance of some of
our ﬁndings. Few reviews are reported as updates of
previously completed reviews. The utility of reviews likely
diminishes over time as they become outdated. Likewise, no
review had a formal registration number. Our study also
provided some disappointing results. For example, publica-
tion bias was considered or assessed in only a minority of
reports despite much evidence for its existence and potential
inﬂuence on the results of reviews [20,21].
However, for therapeutic reviews our comparison of
Cochrane and non-Cochrane reviews provides the most
discouraging results and suggests little improvement in the
quality of reporting of non-Cochrane reviews over time [4,7].
The Cochrane Collaboration has a strict set of policies and
guidance as to how SRs should be conducted and reported.
For example, it is Cochrane policy not to include the words
‘‘systematic review’’ or ‘‘meta-analysis’’ in the review title.
This policy explains why we observed fewer Cochrane reviews
reporting these terms, compared to non-Cochrane ones.
Similarly, Cochrane reviews, because they are reported in an
electronic medium, are not encumbered by word length
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Characteristics of Systematic Reviewsrestrictions as is the case for most paper-based journals.
Electronic publication, along with mechanisms to ensure
adherence to Cochrane policies, allows authors to provide
more complete details of how they conducted their SRs,
possibly explaining why we observed far superior reporting
standards of Cochrane reviews compared to non-Cochrane
therapeutic ones. Journal editors and/or readers, particularly
of specialty journals, might be less interested in these details
and/or not have the resources to monitor adherence to any
set of policies and reporting guidelines.
Many non-Cochrane reviews did not report key aspects of
SR methodology, thus impairing conﬁdence in their results
and conclusions. For example, only 11% of the authors
reported working from a protocol to complete their review,
showing little improvement over time [3]. An examination of
47 Cochrane reviews, for which protocols almost always exist,
revealed that 43 (91.5%) of them reported a major change
such as the addition or deletion of outcomes between the
protocol and the full publication [22].
Strong evidence of outcome reporting bias was recently
reported within clinical trials [23,24]. Our results suggest that
some aspect of selective outcome reporting bias might also
exist within non-Cochrane reviews. Only about one-quarter
of them reported a primary outcome, of which half report
statistical signiﬁcance in favour of this outcome (versus 14.4%
for Cochrane reviews). This issue requires further investiga-
tion.
Results from SRs are most useful when they are up-to-date
[25]. Few reviews were reported as updates and there were
large differences between Cochrane reviews and non-
Cochrane reviews. This difference might reﬂect differing or
nonexistent policies and/or practices across funders, but also
may reﬂect the reluctance of journals to publish updates that
are substantially the same as previous publications. If these
SRs are to retain their currency, updating them needs to be a
much higher priority. This issue is likely to become
increasingly important in coming years.
Clinical trial registration was called for twenty years ago
[26]. In an attempt to minimize or avoid recent questionable
behaviours such as hiding data [27], it is now becoming widely
endorsed by granting agencies, such as the Canadian
Institutes of Health Research [1], and editorial groups, such
as the International Committee of Medical Journal Editors
[28]. Similar behaviours may well affect SRs, although there
are currently few data to inform this belief. Although
protocols of Cochrane reviews are published, no review in
our sample was registered in the usual sense, or had any type
of registration number. Systematic review registration op-
tions exist [29,30] but are not well known. However, the
reasons for registering SRs are likely different from that of
registering clinical trials.
Providing reporting guidance is one way to improve the
above-mentioned deﬁciencies. Real improvements have been
seen in the reporting of RCTs [31] since the introduction of
the CONSORT Statement and endorsement by journals
[32,33] and editorial groups (for example, http://www.icmje.
org). The QUOROM Statement, which provides reporting
guidance for meta-analysis of RCTs, was developed ten years
ago in the hope of having a similar impact on meta-analysis
[34], and there are some indications that its use is associated
with improved quality of reporting [35]. Its uptake was much
slower than was the CONSORT statement, possibly reﬂecting
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Characteristics of Systematic Reviewsthe belief that SRs were less frequently reported and not as
important as RCTs. However, our study shows that currently
about 2,500 such studies are published annually in English
and indexed in Medline. QUOROM is currently being revised,
and when published will provide journals and others with
another opportunity to endorse its use as one way to improve
the reporting of SRs. It is possible that the poor reporting of
some SR categories reﬂects inadequate guidance available to
authors. For example, we are unaware of any reporting
guidance for SRs of prognostic studies.
Efforts directed toward improving reporting standards
come at the end of the research process. Attempts to exert an
inﬂuence much earlier in the research cycle might have a
more profound and lasting effect. One option is to ensure
that the evaluation process by granting agencies requires
prospective applicants and grant peer reviewers to have some
form of experience and expertise with SRs, for example by
providing documentation of SR training. Additionally,
journals might consider asking authors to include their SR
protocols along with the completed review submissions.
Our cross-sectional analysis was limited in that we included
just one month from a single database. It is unlikely, however,
that sampling other months would have changed our results,
as we veriﬁed that the month we chose was a typical entry
month. While we included 300 reviews in our sample the
majority of them were categorized as therapeutic. As such,
our results concerning the other categories should be
interpreted cautiously.
Our examination relied on what the authors reported. It is
possible that the authors more completely conducted their
SRs but omitted important details from their report, or the
peer-review process resulted in the removal of key informa-
tion we sought.
We have not provided here detailed information on several
characteristics, such as the methods used to perform
quantitative data synthesis or assess publication bias. More
detailed information will be forthcoming in additional
reports. Our intent here is to provide the reader with a
broad overview of the reporting characteristics in recently
published SRs.
Finally, we used a broad deﬁnition of what constitutes a SR.
It is possible that a small proportion of our sample were
intended to be literature reviews with very thorough
descriptions of methods employed for the literature search.
However, as such reviews would likely be used to the same
extent as reports that are clearly deﬁned as SRs or whose
authors have quantitatively synthesized the information, we
feel that they are subject to the same susceptibility to bias.
Despite publishing SRs for about half a century, the National
Library of Medicine does not yet index them as a publication
type, at least in part because there is no agreed-upon
deﬁnition of what constitutes a SR [36], although there are
initiatives to help identify them [37]. A publication type for
SRs on Medline is urgently needed.
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Editors’ Summary
Background. In health care it is important to assess all the evidence
available about what causes a disease or the best way to prevent,
diagnose, or treat it. Decisions should not be made simply on the basis
of—for example—the latest or biggest research study, but after a full
consideration of the findings from all the research of good quality that
has so far been conducted on the issue in question. This approach is
known as ‘‘evidence-based medicine’’ (EBM). A report that is based on a
search for studies addressing a clearly defined question, a quality
assessment of the studies found, and a synthesis of the research findings,
is known as a systematic review (SR). Conducting an SR is itself regarded
as a research project and the methods involved can be quite complex. In
particular, as with other forms of research, it is important to do
everything possible to reduce bias. The leading role in developing the SR
concept and the methods that should be used has been played by an
international network called the Cochrane Collaboration (see ‘‘Additional
Information’’ below), which was launched in 1992. However, SRs are now
becoming commonplace. Many articles published in journals and
elsewhere are described as being systematic reviews.
Why Was This Study Done? Since systematic reviews are claimed to be
the best source of evidence, it is important that they should be well
conducted and that bias should not have influenced the conclusions
drawn in the review. Just because the authors of a paper that discusses
evidence on a particular topic claim that they have done their review
‘‘systematically,’’ it does not guarantee that their methods have been
sound and that their report is of good quality. However, if they have
reported details of their methods, then it can help users of the review
decide whether they are looking at a review with conclusions they can
rely on. The authors of this PLoS Medicine article wanted to find out how
many SRs are now being published, where they are being published, and
what questions they are addressing. They also wanted to see how well
the methods of SRs are being reported.
What Did the Researchers Do and Find? They picked one month and
looked for all the SRs added to the main list of medical literature in that
month. They found 300, on a range of topics and in a variety of medical
journals. They estimate that about 20% of reviews appearing each year
are published by the Cochrane Collaboration. They found many cases in
which important aspects of the methods used were not reported. For
example, about a third of the SRs did not report how (if at all) the quality
of the studies found in the search had been assessed. An important
assessment, which analyzes for ‘‘publication bias,’’ was reported as
having been done in only about a quarter of the cases. Most of the
reporting failures were in the ‘‘non-Cochrane’’ reviews.
What Do These Findings Mean? The authors concluded that the
standards of reporting of SRs vary widely and that readers should,
therefore, not accept the conclusions of SRs uncritically. To improve this
situation, they urge that guidelines be drawn up regarding how SRs are
reported. The writers of SRs and also the journals that publish them
should follow these guidelines.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0040078.
  An editorial discussing this research article and its relevance to medical
publishing appears in the same issue of PLoS Medicine
  A good source of information on the evidence-based approach to
medicine is the James Lind Library
  The Web site of the Cochrane Collaboration is a good source of
information on systematic reviews. In particular there is a newcomers’
guide and information for health care ‘‘consumers’’. From this Web
site, it is also possible to see summaries of the SRs published by the
Cochrane Collaboration (readers in some countries can also view the
complete SRs free of charge)
  Information on the practice of evidence-based medicine is available
from the US Agency for Healthcare Research and Quality and the
Canadian Agency for Drugs and Technologies in Health
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